Session » Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis I

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 777

Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study

Abstract Number: 778

Spinal MRI Has Little Incremental Diagnostic Value Compared with MRI of the Sacroiliac Joints Alone in Early Spondyloarthritis

Abstract Number: 779

Changes in Active Inflammatory Lesions Assessed by Magnetic Resonance Imaging: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial

Abstract Number: 780

The Relationship of Inflammation, Fatty Degeneration and the Effect of Long-Term TNF-Blocker Treatment On the Development of New Bone Formation in Patients with Ankylosing Spondylitis

Abstract Number: 781

Ankylosing Spondylitis Is Associated with an Increased Risk of Osteoporotic Fractures: A Population-Based Cohort Study

Abstract Number: 782

Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.